Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of up to $250m over the next eight years by Lilly, to expedite innovation across the pharma pipeline.
The Lilly-Purdue 360 Initiative focuses on several main objectives, including the discovery and rapid delivery of medicines to individuals, connecting the lab discoveries and clinical applications gap, generating a sustainable and resilient supply chain, and developing a workforce.
Go deeper with GlobalData
This partnership is anticipated to yield economic benefits for Indiana, enhancing local innovation.
The previous agreement between the two entities, originally scheduled to conclude in 2027, will now be extended through 2032, with the addition of four new projects.
This initiative will also engage current joint programmes such as Lilly Scholars at Purdue and the Lilly and Purdue Research Alliance Center.
Purdue is said to offer space for Lilly researchers on-site in West Lafayette, while the university’s researchers will partner on Lilly’s facilities in Indianapolis and the LEAP Research and Innovation District of Indiana.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTo achieve the goals, the parties will focus on applying tools that are powered by AI to increase methods of traditional drug discovery, using machine learning advancements and big data analytics for personalised treatments.
The parties noted that they will facilitate technology-enabled approaches to expedite potential treatments from Phase I trials to regulatory approval, as well as technology transfer into manufacturing, which are crucial for Lilly Medicine Foundry.
The collaboration will incorporate AI, data sciences, and robotics to scale manufacturing capacity rapidly, with compliance and sustainability.
Eli Lilly CEO and chair David Ricks said: “Through this expanded collaboration with Purdue, we look forward to combining our strengths in advanced technologies and cutting-edge science to pioneer new methods of delivering next-generation medicines to advance human health.”
The collaboration began in July 2017 with a five-year agreement, where Lilly pledged up to $52m for life science research.
Recently, Alchemab signed a licensing agreement valued at up to $415m with Lilly for ATLX-1282, its investigational antibody therapy targeting amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
